Do you have any prostate cancer patients whose treatments have failed? If so, there's a new option they can try. It's satraplatin, which GPC Biotech is offering under an expanded-access program. Called the Satraplatin Expanded Rapid Access (SPERA) protocol, the program offers hormone-refractory prostate cancer patients whose first-line chemotherapy has failed the investigational drug on a gratis basis. Satraplatin is a fourth-generation oral drug in the platinum family of compounds. For more information, contact 1-(800) 349-8086 or
Driving Primary Vendor Compliance to Increase Pharmacy Purchasing Savings
April 17th 2025This white paper will examine some common—and costly—assumptions about vendor compliance. We’ll show that pharmacies must do more than meet the bare minimum to stay competitive. We’ll also discuss solutions that pharmacies can leverage to optimize compliance, drive savings from their primary vendor, unlock additional pharmacy savings and enhance purchasing.